Literature DB >> 20389138

Molecular pathology in early hepatocarcinogenesis.

Kathryn Effendi1, Michiie Sakamoto.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors characterized by an obvious multistage process of tumor development. Remarkable progress in diagnostic imaging has led to the discovery of small equivocal lesions, now widely recognized as dysplastic nodule, or early HCC. Early HCC is considered a key step in HCC development and progression. However, the molecular pathology involved in early hepatocarcinogenesis remains unclear due to a lack of corresponding experimental models, difficulty in obtaining fresh samples, and an inconsistency in diagnostic criteria. With gene expression profiling, we have currently identified the overexpression of heat-shock protein 70 and cyclase-associated protein 2 as early HCC signatures. We also recently identified the overexpression of the stemness gene Bmi-1 in early HCC. This overexpression was subsequently found to correlate with ATP-binding cassette transporter B1 expression. These findings give new insight into the mechanism of early hepatocarcinogenesis. Nevertheless, further analysis is still necessary to carefully evaluate the roles of these molecular pathology candidates in early hepatocarcinogenesis. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20389138     DOI: 10.1159/000312658

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  9 in total

1.  PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study.

Authors:  Sarka Svobodova; Marie Karlikova; Ondrej Topolcan; Ladislav Pecen; Martina Pestova; Otto Kott; Vladislav Treska; David Slouka; Radek Kucera
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

Review 2.  Clinical significance of cell cycle inhibitors in hepatocellular carcinoma.

Authors:  Yasunobu Matsuda; Toshifumi Wakai; Masayuki Kubota; Masaaki Takamura; Satoshi Yamagiwa; Yutaka Aoyagi; Mami Osawa; Shun Fujimaki; Ayumi Sanpei; Takuya Genda; Takafumi Ichida
Journal:  Med Mol Morphol       Date:  2013-05-03       Impact factor: 2.309

3.  Tumor-derived inducible heat-shock protein 70 (HSP70) is an essential component of anti-tumor immunity.

Authors:  K Dodd; S Nance; M Quezada; L Janke; J B Morrison; R T Williams; H M Beere
Journal:  Oncogene       Date:  2014-03-24       Impact factor: 9.867

4.  Assessment of stromal invasion for correct histological diagnosis of early hepatocellular carcinoma.

Authors:  Fukuo Kondo
Journal:  Int J Hepatol       Date:  2011-06-08

5.  Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma.

Authors:  Zongguo Yang; Liping Zhuang; Peter Szatmary; Li Wen; Hua Sun; Yunfei Lu; Qingnian Xu; Xiaorong Chen
Journal:  Int J Med Sci       Date:  2015-02-15       Impact factor: 3.738

Review 6.  Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring.

Authors:  Li Wang; Min Yao; Zhizhen Dong; Yun Zhang; Dengfu Yao
Journal:  Tumour Biol       Date:  2013-09-05

Review 7.  The eEF1A Proteins: At the Crossroads of Oncogenesis, Apoptosis, and Viral Infections.

Authors:  Wasim Abbas; Amit Kumar; Georges Herbein
Journal:  Front Oncol       Date:  2015-04-07       Impact factor: 6.244

8.  Prognosis of hepatocellular carcinoma patients with bile duct tumor thrombus after hepatic resection or liver transplantation in Asian populations: A meta-analysis.

Authors:  Chenglin Wang; Yu Yang; Donglin Sun; Yong Jiang
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

9.  Curcumin enhances the antitumor effect of ABT-737 via activation of the ROS-ASK1-JNK pathway in hepatocellular carcinoma cells.

Authors:  Ruinian Zheng; Zhijian You; Jun Jia; Shunhuan Lin; Shuai Han; Aixue Liu; Huidong Long; Senming Wang
Journal:  Mol Med Rep       Date:  2015-12-24       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.